Antioxidant-induced apoptosis in vascular smooth muscle cells |
| The invention is based on the discovery that, unlike other cell types, vascular smooth muscle cells ... |
|
Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
| In a method aspect, this invention relates to a method of treating the climacterium symptoms in a ... |
|
Microbial hair tonic composition |
| We claim: 1. A microbial hair treatment composition comprising 10.sup.6 to 10.sup.8 cells/ml of ... |
|
Hair treating composition |
| OF THE INVENTION The formulation of 9 parts d-panthenyl ethyl ether and 1 part d-panthenol can be ... |
|
Hair cosmetic composition |
| We claim: 1. A composition of matter in the form of a solution, comprising: (a) a solvent including ... |
|
Anti-thrombogenic, anti-microbial compositions containing heparin |
| OF THE INVENTION The compositions of the present invention are first dissolved in solvent mixtures ... |
|
Derivative-compound-conjugates and pharmaceutical compositions comprising same |
| OF THE INVENTION The introduction of molecules of diagnostic, prophylactic, or therapeutic ... |
|
Vincamine derivatives and process for the preparation of vincamine and derivatives thereof |
| Having now described our invention what we claim as new and desire to secure by Letters Patent is: 1... |
|
Naphthyridine derivatives and their use as anti-bacterials |
| What we claim is: 1. A 1,8-naphthyridine compound of the formula ##STR9## wherein R is vinyl or 2-... |
|
|
1-arylsulphonyl-2-piperidinone derivatives, process and intermediates for the preparation thereof, their application as antispasmodics and compositions containing them
| Details |
Inventors: Toja, Emilio; Barzaghi, Fernando; Galliani, Giulio;
Assignee: Roussel Uclaf (Paris, FR)
Primary Examiner: Lee; Mary C.
Assistant Examiner: Miltenberger; Lenora
Attorney, Agent or Firm: Stevens, Davis, Miller & Mosher
The invention relates to the products of formula ##STR1## in which R represents the radical ##STR2## in which R.sub.1 at any position on the benzene ring represents linear, branched or cyclic alkyl, alkenyl or alkynyl containing up to 8 carbon atoms, or the radical ##STR3## in which R.sub.2 and R.sub.3, which may be identical or different, represents hydrogen or linear alkyl, alkenyl or alkynyl containing up to 8 carbon atoms or form, together with the nitrogen atom to which they are attached, a carbonaceous heterocyclic radical optionally containing another hetero atom, or the radical OR', R' representing hydrogen, a linear, branched or cyclic alkyl containing up to 8 carbon atoms or aryl containing up to 14 carbon atoms, or the radical SR.sub.4 or S(O)R.sub.5, R.sub.4 and R.sub.5 representing linear, branched or cyclic alkyl, alkenyl, or alkynyl containing up to 8 carbon atoms, or R represents naphthyl optionally substituted with the radical R'.sub.1, R'.sub.1 being as defined above for R.sub.1, to a process and intermediates for the preparation thereof, to their application as medicinal products and to compositions containing them. |
|
DETAILED DESCRIPTION What is claimed is: 1. The compound of formula (I): ##STR11## in which R represents the radical ##STR12## in which R. sub. 1 at any position on the benzene ring represents linear, branched or cyclic alkyl, alkenyl or alkynyl containing up to 8 carbon atoms, or the radical ##STR13## in which R. sub. 2 and R. sub. 3, which may be identical or different, represent hydrogen or linear alkyl, alkenyl or alkynyl containing up to 8 carbon atoms or form, together with the nitrogen atom to which they are attached, a piperidinyl or hexahydroazepinyl radical, or the radical OR', R' representing hydrogen, a linear, branched or cyclic alkyl containing up to 8 carbon atoms or aryl containing up to 14 carbon atoms, or the radical SR. sub. 4 or S(O)R. sub. 5, R. sub. 4 and R. sub. 5 representing linear, branched or cyclic alkyl, alkenyl, or alkynyl containing up to 8 carbon atoms, or R represents naphthyl optionally substituted with the radical R'. sub. 1, R'. sub. 1 being as defined above for R. sub. 1. 2. The compounds of formula (I) as defined in claim 1, in which R represents the radical ##STR14## R. sub. 1 having the same means as in claim 1. 3. The compounds of formula (I) as defined in claim 2, in which the radical R. sub. 1 is at the 4-position. 4. The compound of formula (I) ##STR15## in which R represents the radical ##STR16## in which R. sub. 1 at any position on the benzene ring represents the radical ##STR17## in which R'. sub. 2 and R'. sub. 3, which may be identical or different, represent a linear or branched alkyl containing up to 8 carbon atoms or form, with the nitrogen atom to which they are attached, a piperidinyl or hexahydroazepinyl radical. 5. The compounds of formula (I) as defined in claim 4, in which R'. sub. 2 and R'. sub. 3, which may be identical or different, represent alkyl containing up to 4 carbon atoms. 6. The compounds of formula (I) as defined in claim 4, in which R. sub. 1 represents a piperidinyl radical. 7. The compounds of formula (I) as defined in claim 4, in which R. sub. 1 represents a hexahydroazepinyl radical
|
| Related patents |
|
|
Dihydropyridine derivatives and pharmaceutical composition thereof
OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (I) ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or ...
|
|
|
1-[2-(1H-inden-3-yl)ethyl]-4-(naphth-1-yl)piperazine derivatives, their preparation and their application in therapeutics
We claim: 1. A compound of the formula: ##STR6## in which X represents a hydrogen atom, a C.sub.1 -C.sub.3 alkoxy group or a cyclopropylmethoxy group, and Y represents a ...
|
|
|
Use of fedotozine in the treatment of functional states of intestinal obstructions
We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering a therapeutically effective dose of (+)-1-[(3,4,5-trimethoxy)...
|
|
|
Manufacture of pharmaceutical dosage forms
OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ingestion which are advantageous in a number of particulars over ...
|
|
|
Device comprising liner for protecting fluid sensitive medicament
OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various delivery devices provided by the invention and which examples are not to be ...
|
|
|
In situ active compound assembly
I claim: 1. A method to modify a target condition contained within an environment with a conjugate active in modifying said target condition which conjugate comprises at ...
|
|
|
Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
The invention is directed to a method for the prophylaxis or treatment of an animal for systemic hypotension or other pathogenic syndromes induced by inappropriate ...
|
|
|
Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension
The present invention involves a method for prophylaxis or treatment of an animal for systemic hypotension induced by endotoxin and/or a biological response modifier ...
|
|
|
Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
The inventors herein propose uses of anti-TNF antibodies, anti-endotoxin antibodies, and cytokine receptor antagonists (e.g., IL-1 receptor antagonist) in combination ...
|
|
|
Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor
We claim: 1. A compound having the structural formula I ##STR4## wherein R is cyano, ##STR5## --C(.dbd.X)NHY wherein X is O, S or NH; and Y is hydrogen, hydroxy, alkyl ...
|
|
|